Sponsored by
OX40-Ligand (OX40L) Pathway Resource Center
Highlighting unmet needs in atopic dermatitis (AD) and understanding disease pathogenesis
Expert Insights Roundtable: Amlitelimab STREAM-AD Ph2b
This material is non-promotional and sponsored by Sanofi.
This material is for scientific and medical education purposes only, and is intended only for US healthcare professionals.
This material is for scientific and medical education purposes only, and is intended only for US healthcare professionals.
Amlitelimab is investigational and has not been approved by the US Food and Drug
Administration (FDA) or any other regulatory agency worldwide for the uses under investigation. No conclusions
regarding safety and efficacy should be drawn.
Administration (FDA) or any other regulatory agency worldwide for the uses under investigation. No conclusions
regarding safety and efficacy should be drawn.
© 2025 Sanofi. All Rights Reserved.
Sanofi is a registered trademark of Sanofi or an affiliate.
MAT-US-2410187 v2.0 - R Expiration Date: 10/22/2025